drugset / Trial / NCT04323735
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
Phase 2
Recruiting
182 enrolled
Medstar Health Research Institute
Children's National Research Institute · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
Timeline
- Start
- 2020-01-10
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Culturelle 10 Billion CFU Capsule | Unknown | 2e+10 cells | Intrathecal |
| Comparator | Culturelle 10 Billion CFU Capsule | Unknown | 4e+10 cells | Intrathecal |
Indications
No indication recorded.